← All trials
NCT04284995
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 16, 2020
- Primary completion
- Jul 5, 2020
- Completion date
- Aug 11, 2020
- First posted
- Feb 26, 2020
- Last posted
- Mar 2, 2020
- Enrollment
- 24
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- CeleCor TherapeuticsLead sponsor
- Syneos HealthCollaborator
- Diagram B.V.Collaborator
- St. Antonius Hospital, NieuwegeinCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.